{"transactions":[{"id":3000427,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series C redeemable convertible preferred stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":false,"shares":1320097,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P.."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":191721},"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000426,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series C redeemable convertible preferred stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":false,"shares":1320097,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":191721},"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000425,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series B redeemable convertible preferred stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":false,"shares":5333333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":747321},"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000424,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series B redeemable convertible preferred stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":false,"shares":3333333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":467076},"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000423,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series A redeemable convertible preferred stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":false,"shares":20450000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"Each share of Series A Preferred Stock converted automatically into Common Stock on a 1-for-7.8170 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2616093},"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000422,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"purchase","acquired":true,"shares":235000,"price":15,"value":3525000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held by ARCH Venture Fund VIII, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII, L.P.."}],"balance_after":4512895,"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000421,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":true,"shares":191721,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P.."}],"balance_after":4512895,"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000420,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":true,"shares":191721,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC."}],"balance_after":4512895,"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000419,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":true,"shares":747321,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose."}],"balance_after":4512895,"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000418,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":true,"shares":467076,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC."}],"balance_after":4512895,"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3000417,"issuer":{"id":114958,"kind":"organization","name":"Codiak BioSciences, Inc.","symbol":"CDAK"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2020-10-23T18:38:15.000Z","date":"2020-10-16","kind":"exercise","acquired":true,"shares":2616093,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration.  There was no expiration date for any of the series of preferred stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose."}],"balance_after":4512895,"source":{"system":"sec-edgar","filing":"0000898432-20-000826","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1582681/000089843220000826/form4.xml","form_type":"4"}},{"id":3392939,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series B convertible preferred stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":55556,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":55556},"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}},{"id":3392938,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series B convertible preferred stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-01-16","kind":"exercise","acquired":false,"shares":1111111,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Yukon Investors, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1111111},"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}},{"id":3392937,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series A-1 convertible preferred stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":666667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":666667},"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}},{"id":3392936,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Series A-1 convertible preferred stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-10-16","kind":"exercise","acquired":false,"shares":2222222,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Yukon Investors, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2222222},"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}},{"id":3392935,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-10-16","kind":"purchase","acquired":true,"shares":1500000,"price":20,"value":30000000.0,"ownership":{"direct":true},"balance_after":5555556,"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}},{"id":3392934,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":55556,"ownership":{"direct":false,"nature":"By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."}],"balance_after":5555556,"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}},{"id":3392933,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":1111111,"ownership":{"direct":false,"nature":"By Yukon Investors, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."}],"balance_after":5555556,"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}},{"id":3392932,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":666667,"ownership":{"direct":false,"nature":"By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."}],"balance_after":5555556,"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}},{"id":3392931,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":96361,"kind":"organization","name":"Alaska Permanent Fund Corp","position":1,"cik":"0001582681","reported_name":"Alaska Permanent Fund Corp","relationship":{"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2019-10-16T20:33:12.000Z","date":"2019-10-16","kind":"exercise","acquired":true,"shares":2222222,"ownership":{"direct":false,"nature":"By Yukon Investors, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the issuer's initial public offering, the Series A-1 convertible preferred stock and Series B convertible preferred stock converted automatically into Common Stock on a 1-for-1 basis without payment of further consideration.  There was no expiration date for the Series A-1 convertible preferred stock or Series B convertible preferred stock. On September 27, 2019, prior to the closing of the issuer's initial public offering, the issuer effected a 1-for-4.5 reverse stock split of its common stock and convertible preferred stock which is reflected in the numbers above."}],"balance_after":5555556,"source":{"system":"sec-edgar","filing":"0000898432-19-001253","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000089843219001253/form4.xml","form_type":"4"}}]}